Our Pipeline



RVT-501 is a highly potent and specific topical formulation of a PDE4 inhibitor. Dermavant is currently progressing RVT-501 through a phase 2 clinical trial assessing the safety and efficacy of the therapy in patients with mild-to-moderate Atopic Dermatitis (AD).


RVT-502 is a topical formulation of the JAK/Syk inhibitor cerdulatinib. Dermavant is developing RVT-502 for the treatment of multiple moderate-to-severe inflammatory skin diseases.


RVT-201 is an oral caspase-1 inhibitor that acts to inhibit the production of inflammatory cytokines such as IL-ß and IL-18. Dermavant is developing RVT-201 for mild-to-severe inflammatory skin diseases.